Solutions for Unmet Medical Needs
Incyte (incyte.com) earns a Brand Analyzer score of 87 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 4025 Healthcare brands analyzed, Incyte ranks in the 95th percentile (category average 73, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 100/100, Visual Identity 79/100, Messaging Clarity 95/100, Trust Foundation 97/100, AI Discoverability 70/100, Brand Authority 64/100.
Incyte is an American biopharmaceutical company founded in 2001 and headquartered in Wilmington, Delaware. It focuses on the discovery, development, and commercialization of novel medicines in hematology, oncology, and inflammation and autoimmunity. The company aims to address serious unmet medical needs for patients with limited treatment options, working with healthcare providers, researchers, and industry partners worldwide.
| Brand Name | Incyte |
|---|---|
| Domain | incyte.com |
| Industry | Healthcare |
| Founded | 2001 |
| Headquarters | Wilmington |
| Main Competitors | Bristol Myers Squibb (84/100), Novartis (73/100), AbbVie (84/100), Pfizer (89/100), Gilead Sciences (81/100), Regeneron Pharmaceuticals (77/100), Merck & Co. (81/100) |
Moz Domain Authority 55/100 vs category average 36 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #135,324 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Incyte has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and commercialization of nov…" (Meta description: 25 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, og:title, og:description, og:image, og:type, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on LinkedIn, X (Twitter), Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Incyte scores 60/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Incyte has a moderate AI-visibility profile at 60/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is recommendation likelihood (52/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #135,324 (Tranco). The main gaps holding it back: no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Incyte from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Incyte?", Claude could identify the brand as of August 2026. Incyte is a biopharmaceutical company based in Wilmington, Delaware, known for developing and marketing targeted therapies, particularly in oncology and inflammation/autoimmune diseases. Its flagship product is Jakafi (ruxolitinib), a JAK inhibitor used to treat myelofibrosis, po Best known for Developing Jakafi (ruxolitinib), a JAK inhibitor for myeloproliferative disorders and graft-versus-host disease.
When asked "Best brands similar to Incyte?", Claude would recommend Incyte as of August 2026. Incyte is a well-established biopharma player with a strong oncology and inflammation portfolio, making it relevant when discussing leading specialty pharmaceutical companies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Incyte's main competitors include Bristol Myers Squibb (84/100), Novartis (73/100), AbbVie (84/100), Pfizer (89/100), Gilead Sciences (81/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Incyte and Pfizer are competitors in Healthcare. Brand Analyzer scores Incyte at 87/100 and Pfizer at 89/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Incyte include Bristol Myers Squibb (84/100), Novartis (73/100), AbbVie (84/100), Pfizer (89/100), Gilead Sciences (81/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Incyte is an American global biopharmaceutical company founded in 2001 and headquartered in Wilmington, Delaware. It is dedicated to the discovery, development, and commercialization of novel medicines for serious unmet medical needs.
Sources: Incyte official site
Incyte has moderate AI-search visibility, scoring 60/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 52, recommendation 52). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Incyte official site
Incyte was founded in 2001. Incyte operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Incyte is headquartered in Wilmington. Incyte operates in the Healthcare category.
Sources: Wikidata
Incyte discovers, develops, and commercializes novel medicines, with a primary focus on hematology, oncology, and inflammation and autoimmunity. It conducts scientific research aimed at creating breakthrough therapies for patients who have limited existing treatment options.
Sources: Incyte official site
Incyte scores 52/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Incyte official site
Incyte can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Incyte official site
Incyte develops and commercializes novel medicines targeting hematologic and oncologic conditions, as well as inflammatory and autoimmune disorders. The company's work centers on translating scientific research into new therapeutic options for patients with serious diseases.
Sources: Incyte official site
Incyte's work serves patients suffering from serious diseases such as cancers and inflammatory disorders, as well as healthcare providers, researchers, and industry partners who rely on or contribute to its pharmaceutical research and products.
Sources: Incyte official site
Incyte is known for its focus on developing innovative therapies in the fields of hematology, oncology, and inflammation and autoimmunity, targeting diseases with significant unmet medical needs.
Sources: Incyte official site
Ranked closest to Incyte: IDBS (87/100), ICICI Lombard (87/100), Inovalon (87/100), Jenoptik (87/100).
A step up - brands to learn from: theSkimm (91/100), Oura (91/100).
Category leader: Elsevier (96/100).